SHAILY ENG PLASTICS LTD

Designs, develops and manufactures precision-engineered plastic components and finished drug-delivery devices across healthcare, consumer durables and industrial segments. The healthcare business surged 139% in FY26 to INR393 crore and contributed 40% of consolidated revenue, anchored on the proprietary ShailyPen Neo spring-driven pen injector platform used in Semaglutide combination products — the firm handles full design-to-manufacture of device components for pharma partners and has secured a INR423 crore pen injector order over 4 years, holding 70% share among the top-6 Canadian filers. Consumer durables revenue stood at INR511 crore in FY26 (down 9% YoY), and industrial revenue at INR87 crore (up 41% YoY). FY26 consolidated revenue was INR991 crore, exports contributing ~68%, and machine utilisation reaching 47.6%. New vertical entry includes semiconductor trays (sole Indian manufacturing partner for a Korean customer, supplies from Q4 FY27) and consumer electronics precision components (a ~INR100 crore South India plant). A 25 million pen capacity line is ramping, with a second 25 million line due Jul-Aug 2026; pen volume targets are 36 million in FY27 and ~50 million in FY28. Materials are the largest cost at 44% of revenue, capex runs at 18% of revenue, and the board has approved an enabling resolution to raise up to INR500 crore.